Drug Profile

Insulin/pramlintide - Amylin/Breakthrough T1D

Alternative Names: Pramlintide/insulin

Latest Information Update: 13 Sep 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Amylin Pharmaceuticals; JDRF
Developer AstraZeneca; Breakthrough T1D
Class Antihyperglycaemics; Insulins; Macromolecular substances; Pancreatic hormones; Proteins
Mechanism of Action Amylin receptor agonists; Ornithine decarboxylase stimulants; Phosphokinase stimulants; Protein tyrosine kinase stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

28 Sep 2018 No recent reports of development identified for phase-I development in Type-1 diabetes mellitus in USA (SC, Infusion)
01 Aug 2016 AstraZeneca completes a phase I trial for Type-1 diabetes mellitus in USA (NCT02500979)
08 Aug 2012 Amylin Pharmaceuticals has been acquired by Bristol-Myers Squibb

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com